All In Biotech

Drug Trial Radar · NCT00538343

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

14

Actual

Start

Oct 31, 2007

Primary completion

Dec 1, 2008

Study completion Jan 1, 2009

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Oct 2, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.

Conditions

  • Brain Metastases

Interventions

  • berubicin hydrochloride (RTA 744)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of RTA 744 in reducing intracranial tumor on contrast-enhanced MRI of breast cancer patients with progression of brain metastases following whole brain radiotherapy (WBRT).Time frame: 21 Days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Palm Beach Cancer Institute

    West Palm Beach, Florida

  • Presbyterian Health Care

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Moses Cone Regional Cancer Center

    Greensboro, North Carolina

  • Forsyth Regional Cancer Center

    Winston-Salem, North Carolina

  • Texas Oncology, PA

    Dallas, Texas

  • Virginia Oncology Associates

    Newport News, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.